2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5215 Prognostic differences between IDH2-R172 and IDH2-R140 in AML: The role of NPM1 co-mutation

Paloma Resende, MD, Tarcila Santos Datoguia, MD2, Aline Raposo Nishimoto, MD3, Andre Meireles, MD4, Lucila Nassif Kerbauy, MD, PhD5, Mariana Nassif Nassif Kerbauy, MD, PhD6, Lucas Tejo Pereira de Brito Silva, MD7, Alexandre Eiji Eiji Kayano, MD8, Danielle Ovigli Lopes, MD9, Elvira Velloso Sr, Dr10, Andreza Feitoza Ribeiro, MD11, Nelson Hamerschlak Sr, MD PhD12, Fabio Pires S Santos, MD, PhD13
1 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
2 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
3 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
4 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
5 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
6 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
7 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
8 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
9 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
10 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
11 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
12 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
13 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil

Background: IDH2 mutations occur in 10% to 12% of patients with acute myeloid leukemia (AML) and most commonly involve R140 or R172. R140 is more frequent and often co-occurs with NPM1 mutations, whereas R172 is less common and has shown inconsistent prognostic associations across studies. We compared the prognosis of IDH2-R140 and IDH2-R172 AML while accounting for NPM1 status and ELN 2022 risk.

Methods: We pooled data from 14 public cohorts and included patients with AML, documented survival, and an IDH2 mutation annotated at the amino acid level (R140, n=445; R172, n=115). Nineteen patients with concurrent IDH1 mutations were excluded. Median follow-up was 66.7 months. Overall survival was compared using Kaplan-Meier analysis and mixed-effects Cox regression, with cohort included as a random effect. Models were adjusted for age and ELN 2022 risk, which was derived from available mutational and cytogenetic data. Additional analyses were restricted to patients with NPM1-wild-type AML, comparing each IDH2 group with IDH-wild-type AML from the same cohorts (n=4,205).

Results: Patients with IDH2-R172 had longer survival than those with IDH2-R140. Median survival was 35.1 months (95% CI, 24.9 to not reached) versus 20.6 months (95% CI, 17.4–24.7), and 2-year survival was 60.0% versus 46.2% (log-rank p=0.0045). The difference remained significant after adjustment for age and ELN 2022 risk (HR, 0.65; 95% CI, 0.49–0.87; p=0.004).

ELN 2022 classified 162 of 445 patients with R140 as favorable risk, compared with 3 of 115 patients with R172. Among the 162 favorable-risk R140 cases, 152 had NPM1 mutations without FLT3-ITD. Co-mutation patterns also differed between the two groups. NPM1 mutations were present in approximately half of R140 cases but in only 2.6% of R172 cases (OR, 37.3; p<0.0001). In contrast, DNMT3A mutations were more frequent with R172 than with R140 (62.6% vs 37.6%; p<0.001). SRSF2 mutations and FLT3-ITD were more frequent in R140 cases.

Because ELN 2022 classifies NPM1-mutated, FLT3-ITD-negative AML as favorable risk, adjustment for ELN may absorb part of the prognostic effect associated with NPM1. We therefore analyzed the NPM1-wild-type subgroup (n=334). In this group, survival remained longer with R172, and the difference was larger than in the overall cohort. Median survival was 41.7 months with R172 and 15.1 months with R140 (log-rank p<0.0001; HR, 0.50; 95% CI, 0.37–0.69). In a model that included NPM1, FLT3-ITD, and complex karyotype directly rather than through ELN 2022, the association also remained significant (HR, 0.57; 95% CI, 0.41–0.78; p<0.001).

Compared with IDH-wild-type AML from the same cohorts, R140 was not associated with a difference in survival (HR, 0.92; 95% CI, 0.82–1.04; p=0.20), whereas R172 was associated with longer survival (HR, 0.53; 95% CI, 0.41–0.68; p<0.001). The association with R172 remained significant after adjustment for TP53 mutations, complex karyotype, NPM1 mutations, and FLT3-ITD instead of ELN 2022 risk (HR, 0.66; 95% CI, 0.51–0.86; p=0.002).

The main limitation was the distribution of R172 cases across cohorts. Approximately 85% came from two cohorts. Among the remaining cohorts, only 17 patients with R172 had follow-up data, with 11 events. The adjusted estimate in this subset was imprecise (HR, 1.01; 95% CI, 0.47–2.18; p=0.98) and could not establish or exclude generalizability.

Conclusion: IDH2-R172 AML was associated with longer survival than IDH2-R140 AML. This difference remained after accounting for NPM1 and was more pronounced among patients with NPM1-wild-type disease. Differences in the prevalence of NPM1 co-mutation may explain the inconsistent results reported in previous series. IDH2 mutations should therefore be reported and analyzed by codon rather than as a single category, although independent validation is needed.

Paloma Resende, MD: BeOne - Honoraria; CSL Behring - Honoraria